We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > drops price

News List

Gene therapy drug Kymriah should be publicly covered if manufacturer drops price, report recommends firstwordpharma
January 17, 2019
An expert panel convened by the Canadian Agency for Drugs and Technologies in Health (CADTH) concluded that Novartis' gene therapy Kymriah should be publicly covered provided the company lowers its price, The Globe and Mail reported.
Gene therapy drug Kymriah should be publicly covered if manufacturer drops price, report recommends firstwordpharma
January 17, 2019
An expert panel convened by the Canadian Agency for Drugs and Technologies in Health (CADTH) concluded that Novartis' gene therapy Kymriah should be publicly covered provided the company lowers its price, The Globe and Mail reported.